|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 10 (May 15), 2000:
pp. 3219-3222
Chronic neutropenia mediated by Fas ligand
Jin Hong Liu,
Sheng Wei,
Thierry Lamy,
P.
K. Epling-Burnette,
Gordon Starkebaum,
Julie Y. Djeu, and
Thomas P. Loughran Jr
From the H. Lee Moffitt Cancer Center and Research Institute, the
Veterans Administration Hospital, and the Departments of Internal
Medicine, Immunology/Microbiology, and Biochemistry/Molecular Biology;
University of South Florida, College of Medicine, Tampa, FL; and the
Veterans Administration Puget Sound Health Care System and Department
of Medicine, University of Washington School of Medicine, Seattle, WA.
Chronic neutropenia, often associated with rheumatoid arthritis, is
a characteristic finding in large granular lymphocyte (LGL) leukemia.
The mechanism of neutropenia is not known. Normal neutrophil survival
is regulated by the Fas-Fas ligand apoptotic system. We hypothesized
that neutropenia in LGL leukemia is mediated by dysregulated expression
of Fas ligand. Levels of Fas ligand in serum samples from patients with
LGL leukemia were measured with a Fas ligand enzyme-linked
immunosorbent assay. The effects of serum from patients with LGL
leukemia on apoptosis of normal neutrophils were determined by flow
cytometry and morphologic assessment. High levels of circulating Fas
ligand were detected in 39 of 44 serum samples from patients with LGL
leukemia. In contrast, Fas ligand was undetectable in 10 samples from
healthy donors. Serum from the patients triggered apoptosis of normal neutrophils that depended partly on the Fas pathway. Resolution of
neutropenia was associated with disappearance or marked reduction in
Fas ligand levels in 10 of 11 treated patients. These data suggest that
high levels of Fas ligand are a pathogenetic mechanism in human disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Zambello and G. Semenzato
Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches
Haematologica,
October 1, 2009;
94(10):
1341 - 1345.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Mohan, M. J. Clemente, M. Afable, H. N. Cazzolli, N. Bejanyan, M. W. Wlodarski, A. E. Lichtin, and J. P. Maciejewski
Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia
Haematologica,
October 1, 2009;
94(10):
1407 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Moallem and J. M. Koenig
Preeclampsia and Neonatal Neutropenia
NeoReviews,
September 1, 2009;
10(9):
e454 - e459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Hodge, J. Yang, M. D. Buschman, P. M. Schaughency, H. Dang, W. Bere, Y. Yang, R. Savan, J. J. Subleski, X.-M. Yin, et al.
Interleukin-15 Enhances Proteasomal Degradation of Bid in Normal Lymphocytes: Implications for Large Granular Lymphocyte Leukemias
Cancer Res.,
May 1, 2009;
69(9):
3986 - 3994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Chen, F. Bai, L. Sokol, J. Zhou, A. Ren, J. S. Painter, J. Liu, D. A. Sallman, Y. A. Chen, J. A. Yoder, et al.
A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia
Blood,
April 2, 2009;
113(14):
3226 - 3234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. O. Huh, L. J. Medeiros, F. Ravandi, S. Konoplev, J. L. Jorgensen, and R. N. Miranda
T-Cell Large Granular Lymphocyte Leukemia Associated With Myelodysplastic Syndrome: A Clinicopathologic Study of Nine Cases
Am J Clin Pathol,
March 1, 2009;
131(3):
347 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Elbim, V. Monceaux, Y. M. Mueller, M. G. Lewis, S. Francois, O. Diop, K. Akarid, B. Hurtrel, M.-A. Gougerot-Pocidalo, Y. Levy, et al.
Early Divergence in Neutrophil Apoptosis between Pathogenic and Nonpathogenic Simian Immunodeficiency Virus Infections of Nonhuman Primates
J. Immunol.,
December 15, 2008;
181(12):
8613 - 8623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Link and T. Wun
Myeloid disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
143 - 171.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Schade, J. J. Powers, M. W. Wlodarski, and J. P. Maciejewski
Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis
Blood,
June 15, 2006;
107(12):
4834 - 4840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sokol and T. P. Loughran Jr.
Large granular lymphocyte leukemia.
Oncologist,
March 1, 2006;
11(3):
263 - 273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Peng
Fas (CD95)-related apoptosis and rheumatoid arthritis
Rheumatology,
January 1, 2006;
45(1):
26 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Lima, J. Almeida, A. G. Montero, M. d. A. Teixeira, M. L. Queiros, A. H. Santos, A. Balanzategui, A. Estevinho, M. d. C. Alguero, P. Barcena, et al.
Clinicobiological, Immunophenotypic, and Molecular Characteristics of Monoclonal CD56-/+dim Chronic Natural Killer Cell Large Granular Lymphocytosis
Am. J. Pathol.,
October 1, 2004;
165(4):
1117 - 1127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Rose and N. Berliner
T-Cell Large Granular Lymphocyte Leukemia and Related Disorders
Oncologist,
June 1, 2004;
9(3):
247 - 258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Goepel, P. Weinmann, J. Schymeinsky, and B. Walzog
Identification of caspase-10 in human neutrophils and its role in spontaneous apoptosis
J. Leukoc. Biol.,
May 1, 2004;
75(5):
836 - 843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. O'Keefe, M. Plasilova, M. Wlodarski, A. M. Risitano, A. R. Rodriguez, E. Howe, N. S. Young, E. Hsi, and J. P. Maciejewski
Molecular Analysis of TCR Clonotypes in LGL: A Clonal Model for Polyclonal Responses
J. Immunol.,
February 1, 2004;
172(3):
1960 - 1969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Horwitz, R. S. Negrin, K. G. Blume, S. Breslin, M. J. Stuart, K. E. Stockerl-Goldstein, L. J. Johnston, R. M. Wong, J. A. Shizuru, and S. J. Horning
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
Blood,
February 1, 2004;
103(3):
777 - 783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Berliner, M. Horwitz, and T. P. Loughran Jr.
Congenital and Acquired Neutropenia
Hematology,
January 1, 2004;
2004(1):
63 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Papadaki, K. Stamatopoulos, A. Anagnostopoulos, and A. Fassas
Rituximab-associated immune myelopathy
Blood,
August 15, 2003;
102(4):
1557 - 1558.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Bigouret, T. Hoffmann, L. Arlettaz, J. Villard, M. Colonna, A. Ticheli, A. Gratwohl, K. Samii, B. Chapuis, N. Rufer, et al.
Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors
Blood,
April 15, 2003;
101(8):
3198 - 3204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Papadaki, A. G. Eliopoulos, T. Kosteas, C. Gemetzi, A. Damianaki, H. Koutala, J. Bux, and G. D. Eliopoulos
Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells
Blood,
April 1, 2003;
101(7):
2591 - 2600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shi, G. E. Gilbert, Y. Kokubo, and T. Ohashi
Role of the liver in regulating numbers of circulating neutrophils
Blood,
August 15, 2001;
98(4):
1226 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Connolly, Y. H. Cho, R. Duan, J. Fikes, T. Gregorio, D. W. LaFleur, Z. Okoye, T. W. Salcedo, G. Santiago, S. Ullrich, et al.
In Vivo Inhibition of Fas Ligand-Mediated Killing by TR6, a Fas Ligand Decoy Receptor
J. Pharmacol. Exp. Ther.,
July 1, 2001;
298(1):
25 - 33.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. M. Konstadoulakis, E. G. Messaris, S. Hashimoto, A. Kobayashi, and H. Nakajima
ARE CANCER PATIENTS ADEQUATE CANDIDATES FOR STUDYING APOPTOSIS IN SEPTIC AND ARDS MODELS?
Am. J. Respir. Crit. Care Med.,
May 1, 2001;
163(6):
1500 - 1500.
[Full Text]
[PDF]
|
|
|
|
|
